Carl DeSelm

Medicine & Life Sciences

1. Chimeric Antigen Receptors 100%
2. Radiotherapy 71%
3. Osteoclasts 71%
4. T-Lymphocytes 64%
5. Cell- and Tissue-Based Therapy 56%
6. Recurrence 44%
7. RANK Ligand 39%
8. Pancreatic Neoplasms 36%
9. Uterine Cervical Neoplasms 34%
10. Bone Resorption 34%
11. Neoplasms 33%
12. Osteoporosis 32%
13. halofuginone 32%
14. Survival 32%
15. Adoptive Immunotherapy 31%
16. Estrogens 30%
17. Adenocarcinoma 30%
18. Re-Irradiation 29%
19. Interleukin-17 29%
20. Cell Death 28%
21. Radiation 27%
22. Human immunodeficiency virus 1 p16 protease 27%
23. Caspase Activation and Recruitment Domain 27%
24. Secretory Component 26%
25. Radioimmunotherapy 25%
26. Paxillin 25%
27. Breast Neoplasms 23%
28. Glucose 23%
29. Bone and Bones 22%
30. Intensity-Modulated Radiotherapy 22%
31. Inflammasomes 22%
32. Osteoblasts 22%
33. Osteogenesis 21%
34. Non-Hodgkin's Lymphoma 21%
35. Contracts 21%
36. Nasopharyngeal Carcinoma 21%
37. Breast 19%
38. Protons 18%
39. Head and Neck Neoplasms 18%
40. Cytoskeleton 18%
41. Autophagy 17%
42. Proton Therapy 17%
43. Names 17%
44. CA-19-9 Antigen 17%
45. Dendritic Cells 16%
46. HIV-1 16%
47. Proteins 15%
48. Drug Therapy 15%
49. Radiation Oncology 14%
50. Lysosomes 14%